David Allmond announced as CEO following decision by Graham Mullis to retire

Paris, France and Camberley, UK – 29 July 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a leading international specialist in clinical diagnostics, announces the appointment of David Allmond as CEO and a member of the Board of Directors effective from 18 October 2021. At that time Graham Mullis, having informed the Board that he wishes to retire after 13 years with the expanded Group, will stand down as CEO and board member.

https://novacyt.com/wp-content/uploads/2021/07/Novacyt-David-Allmond-announced-as-CEO-following-decision-by-Graham-Mullis-to-retire.pdf